Preparation and Characterization of Sugar Cane Wax Microspheres Containing Indomethacin
Purpose: To formulate and characterize indomethacin (IM) microspheres prepared with sugar cane wax microsperes.
Methods: Microspheres were prepared by melt-emulsified dispersion and cooling-induced solidification method. The microspheres were characterized by scanning electron microscopy (SEM) and differntial scanning calorimetry (DSC) as well as for drug loading, and in vitro and in vivo release in albino sheeps. Results: SEM images showed that the microspheres were spherical in shape and more than 98.0 % of the isolated microspheres were in the size range 345 - 360 μm. The Cmax, Tmax, AUCO - 24 and T1/2 values were 2123 ± 30 ng/ml, 3.1 h, 9734 ± 126 ng/ml h−1, and 2.68 ± 0.03 h−1 for the reference product, Microcid® SR, and 1989 ± 26 ng/ml, 3.0 h, 8013 ± 79 ng/ml h−1, and 2.79 ± 0.12 h−1, respectively, for the test formulation.
Conclusion: Based on this study, it can be concluded that the developed indomethacin-loaded wax microsheres and Microcid® SR capsule are bioequivalent in terms of rate and extent of absorption.
Keywords: Indomethacin, Bioavailability, Controlled release Sugarcane wax, Release kinetics.
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.